论文部分内容阅读
目的观察羟基喜树碱（HCPT），5一氟尿嘧啶（5－FU）和阿霉素（ADM）联合化疗治疗胃癌的疗效和耐受性。方法42例胃癌患者接受HCPT10mg静滴，第1～5天；5－FU750mg，静滴第1～3天；ADM50mg静滴第1天的联合化疗。每3周为一疗程。结果可评价疗效患者24例，总缓解率41．7％（10／24），完全缓解率（CR）8．3％（3／24），部分缓解率（PR）33．3％（8／24）。可评价毒性患者42例，白细胞减少发生率为88％（3～4度仅4．7％），血红蛋白减少和血小板减少分别为19％和28．5％。脱发为100％。其他毒副反应少见。结论以HCPT为主组成的FAHCPT方案治疗胃癌有一定疗效，且毒性可耐受。
Objective To observe the efficacy and tolerability of HCPT, 5-fluorouracil (5-FU) and adriamycin (ADM) in the treatment of gastric cancer. Methods Forty-two patients with gastric cancer received intravenous infusion of 10 mg of HCPT for 1 to 5 days, 5-FU of 750 mg for 1 to 3 days of intravenous infusion, and ADM 50 mg of intravenous infusion on the first day of combined chemotherapy. Every 3 weeks is a course of treatment. Results 24 patients were evaluated for efficacy. The total response rate was 41.7% (10/24), the complete response rate (CR) was 8.3% (3/24), and the partial response rate (PR) was 33.3% (8/ twenty four). Among 42 patients who could be evaluated for toxicity, the incidence of leukopenia was 88% (4.7% for 3 to 4 degrees), and hemoglobin reduction and thrombocytopenia were 19% and 28.5%, respectively. Hair loss is 100%. Other toxic and side effects are rare. Conclusion The HCPT-based FAHCPT regimen has a certain therapeutic effect on gastric cancer, and its toxicity can be tolerated.